Author:
Sachdeva Rakhee,Kumar Narender,Brache Vivian,Friedland Barbara A.,Plagianos Marlena,Zhang Shimin,Kizima Larisa,Cochon Leila,Tabar Ana Sofía Tejada,Blanc Ann,Merkatz Ruth B.
Abstract
AbstractTo identify biomarkers of hormonal contraceptive (HC) use in urine and saliva, we conducted a pilot study with 30 women initiating levonorgestrel (LNG) containing combined oral contraceptives (COCs) or depot medroxyprogesterone acetate (DMPA) (15/group). Based on established COC pharmacokinetics, we collected serum and urine samples before COC ingestion and during Days one and three of use, or before DMPA injection and on Days 21 and 60 post-injection. We used liquid chromatography-tandem mass spectrometry (LC–MS/MS) to measure serum/urine LNG and MPA. LNG was undetectable at baseline (specificity 100%); post ingestion, most urine samples had detectable LNG levels (sensitivity: 80% 6 h post Dose one, 93% 6 h post Dose three). We used a DetectX LNG immunoassay kit and showed 100% sensitivity measuring urine LNG. Urine MPA levels were undetectable in 14/15 women at baseline (specificity 91%); post-injection all urine samples had detectable MPA levels (sensitivity: 100% days 21 and 60). Results suggest urine sampling can be used to identify a biomarker of LNG and MPA use. Based on evidence from other steroidal hormonal studies showing changes affecting the transcriptome profile of saliva at 24 h, we used the same (COC, DMPA) timepoints to collect saliva. We performed transcriptome analysis and detected several differentially expressed genes in DMPA users’ saliva on Days 21 and 60 compared to baseline; none among COC users. We plan further research of differential gene expression in saliva as a HC biomarker of DMPA use, and will explore longer periods of COC use and saliva collection times, and application of microRNA sequencing to support using saliva as a COC biomarker.
Funder
Johns Hopkins University via Bill & Melinda Gates Foundation
Publisher
Springer Science and Business Media LLC
Reference46 articles.
1. Sustainable Development Goals and Family Planning 2020: International Planned Parenthood Federation (IPPF). https://www.ippf.org/sites/default/files/201611/SDG%20and%20FP2020.pdf. Accessed 20 Feb 2018.
2. Ahmed, S. et al. Trends in contraceptive prevalence rates in sub-Saharan Africa since the 2012 London Summit on Family Planning: Results from repeated cross-sectional surveys. Lancet Glob. Health. 7(7), e904–e911. https://doi.org/10.1016/S2214-109X(19)30200-1 (2019).
3. Beatty, A. The determinants of recent trends in fertility in Sub-Saharan Africa. National Acad. Sci. Eng. Med. https://doi.org/10.17226/21857 (2015).
4. Brown, M. T. et al. Medication adherence: Truth and consequences. Am. J. Med. Sci. 351, 387–399. https://doi.org/10.1016/j.amjms.2016.01.010 (2016).
5. Leahy, M. E., Bernice, K. & John, R. Tracking changes in states of contraceptive use over time in Sub-Saharan Africa through cohort and period analyses. J. Biosoc. Sci. 47, 329–344. https://doi.org/10.1017/s0021932014000108 (2015).
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献